Anavex Life Sciences Corp. entered into a Sales Agreement with TD Securities $(USA)$ LLC on July 25, 2025, allowing for the offer and sale of up to $150,000,000 in shares of common stock. The transactions, which may occur through various methods including "at the market offerings," do not specify the total number of shares or the price per share in the document. Both parties have the right to suspend or terminate the offering, and TD Securities will receive a commission of up to 3.0% of the gross proceeds from sales.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-25-001033), on July 28, 2025, and is solely responsible for the information contained therein.